



## Guidance Document on DEA X-Waiver Changes for Buprenorphine Prescribing

**Updated 5/28/2021**

**On April 27, 2021, the US Department of Health and Human Services issued new practice guidelines regarding the waiver process for medical providers wishing to prescribe buprenorphine to patients with opioid use disorder.**

**Please be advised that this change still requires a prescriber to obtain a DEA X-waiver to prescribe buprenorphine for opioid use disorder.**

### **New Changes to Guidelines**

- Up to 30 patients can be treated without completing X-waiver training. **NOTE: You still need to submit a notice of intent (i.e., an X-waiver is still required).**
- Up to 100 patients can be treated once the Controlled Substance Act (X-waiver) training is completed.

These federal changes do not impact the requirements of practitioners to comply with the following rule chapters:

Medical Board: OAC [4731-33](#) (Physicians) | OAC [4730-4](#) (Physician Assistants)

Nursing Board: OAC [4723-9](#)

### **For More Information**

**HHS FAQ:** <https://www.samhsa.gov/medication-assisted-treatment/practitioner-resources/faqs>

**Quick Start Guide:** <https://www.samhsa.gov/sites/default/files/quick-start-guide.pdf>

